K-Mab

K-Mab Biopharma is a clinical-stage biotechnology company based in Suzhou, China, specializing in the discovery and development of fully human therapeutic monoclonal antibodies. The company leverages its proprietary K-Mab™ transgenic mouse platform, which is engineered to generate high-affinity, fully human antibodies that minimize immunogenicity risks in clinical settings. K-Mab Biopharma's internal pipeline is primarily focused on oncology and immunology, with lead programs targeting validated and emerging checkpoints such as Claudin 18.2 and CD47. By integrating its advanced antibody discovery engine with comprehensive biologics development capabilities, the company aims to deliver innovative therapies to address significant unmet medical needs globally. K-Mab Biopharma also engages in strategic partnerships to maximize the utility of its platform for external drug discovery projects.